Stock Market & Financial Investment News

Celgene EPS guidance likely to rise throughout 2014, says CantorAfter Celgene reported in-line Q4 EPS, Cantor thinks that investors have decided that the company's growth will moderate going forward. The firm does not expect this to occur, and it keeps a $186 price target and Buy rating on the shares.

Celgene price target raised to $155 from $130 at ArgusArgus increased its price target on Celgene as the firm thinks the company is "well on its way" to meeting its growth targets. The firm thinks the company reported strong Q4 results and keeps a Buy rating on the shares.

Celgene reports Abraxane now reimbursed in Italy as first-line treatmentCelgene International SÓrl, a wholly owned subsidiary of Celgene Corporation, announced that Italian authorities have issued a positive decision for NHS reimbursement of ABRAXANE -- paclitaxel formulated as albumin-bound nanoparticles, or nab-paclitaxel -- in combination with gemcitabine, for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas, or pancreatic cancer. The reimbursement decision has been published in the Italian Official Gazette no. 30, dated February 6, 2015.